NDAORALCAPSULE
Approved
Feb 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RESTORIL (temazepam) is an oral benzodiazepine capsule approved in 1981 for the short-term treatment of insomnia. It works by enhancing GABA-mediated inhibition in the central nervous system to promote sleep initiation and maintenance. This is a mature, established therapy in a crowded sedative-hypnotic market.
$0.984MPart D
LOE ApproachingProduct is in end-of-life phase with minimal Part D spending and low claim volume; team restructuring and consolidation are likely.
Mechanism of Action
Pharmacologic Class:
Benzodiazepine
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study to Investigate the Effects of Melatonin, Temazepam & Zolpidem on Sleep EEG in Men and Women
Started Jul 2009
16 enrolled
Insomnia
Career Relevance
Working on Restoril offers limited career advancement; the product is in end-of-life phase with minimal job posting activity and declining market engagement. Career growth is constrained, and roles are primarily defensive (retention, compliance, managed decline) rather than expansive.
Brand Manager
Worked on RESTORIL at Quantum Genomics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.